E

Syros CEO Nancy Simonian looks forward to an exciting 2018

Interview with Syros Pharma CEO Dr Nancy Simonian

January 9, 2018
E

SABCS18 An in-depth review of key breast cancer trials

A rock around the breast cancer clock with cancer immunotherapies and targeted agents from SABCS18

December 7, 2018
E

SABCS17 Update on CDK4/6 Inhibitors

A look at the latest CDK4/6 inhibitor data including the important phase 3 trial with ribociclib (MONALEESA-7).

December 6, 2017
E

Is Tucatinib better than Neratinib in HER2-positive Breast Cancer?

2017 could well turn out to be a good year for HER2+ breast cancer with several new developments ongoing. We take a look...

January 30, 2017
E

Understanding the Mutational Landscape of Metastatic Breast Cancer

How crowdsourcing data from breast cancer patients may help future clinical R&D

January 24, 2017
E

Targeting Breast Cancer Stem Cells

Will cancer stem cell therapeutics impact the lives of people with metastatic breast cancer?

January 23, 2017
E

Challenges and Opportunities in Inflammatory Breast Cancer

SABCS16 expert interview on Inflammatory Breast Cancer with Dr Naoto Ueno from MD Anderson Cancer Center.

January 17, 2017
E

How circulating tumor DNA could change cancer treatment

SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.

January 16, 2017
E
Dr Leisha Emens SABCS16

Advances in Breast Cancer Immunotherapy

Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens

January 13, 2017
E

Still looking for a JPM17 Licensing Deal? How about a First-in-Class Drug for Metastatic Breast Cancer?

First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.

January 12, 2017
E
The Alamo, San Antonio TX

Emerging Trends from SABCS16 in San Antonio

3 trends from SABCS16 that you may hear more about

December 15, 2016
E

Promising new agents in development for breast cancer

Five promising new agents in development for the treatment of ER+ or HER2+ or triple negative breast cancer emerge from #SABCS15

December 14, 2015
E

Checkpoint therapy update in metastatic breast cancer

Adding chemotherapy or an ADC boosts the immunogenic effects prior to checkpoint therapy in metastatic breast cancers

December 11, 2015
E

Biomarin PARP inhibitor talazoparib shows promise in gBRCA Breast Cancer

Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer

January 9, 2015
E

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015
E

SABCS Update on Triple Negative Breast Cancer

In the last post of 2014, it’s time to address some pertinent questions on triple negative breast cancer (TNBC).

December 19, 2014
E

Do Checkpoint Inhibitors work in Triple Negative Breast Cancer?

There is a lot of interest in checkpoint inhibitors, do they look they will be effective in Triple Negative Breast Cancer?

December 10, 2014
E

AbbVie’s PARP inhibitor veliparib is highly active in triple negative breast cancer

The first readout from the I-SPY2 neoadjuvant breast cancer trial comes from the veliparib (PARP) arm.

December 13, 2013
E

What to watch for at San Antonio Breast Cancer Symposium

A preview of some of the landmark trial data emerging from the 2013 San Antonio Breast Cancer Symposium

December 11, 2013